Endocrine disorders and osteoporosis

Current Opinion in Rheumatology

Volumn 9, Issue 4, 1997, Pages 355-361

  Rosen, Clifford J ^a  

^a ST JOSEPH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE REMODELING; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; ENDOCRINE DISEASE; FRACTURE; HUMAN; HYPERPARATHYROIDISM; HYPERTHYROIDISM; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK;

ENDOCRINE SYSTEM DISEASES; HUMANS; OSTEOPOROSIS;

EID: 0030847816     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199707000-00014     Document Type: Review

References (45)

1. Manolagas SC, Jilka RL: Bone marrow, cytokines and bone remodeling. N Engl J Med 1995, 332:305-311.
2. Bouillon R: Diabetic bone disease. Calcif Tissue Int 1991, 49:155-160.
3. Verhaege J, Suiker AMH, Visser WJ, Van Herck E, Van Bree R, Bouillion R: The effects of systemic insulin, IGF-I and GH on bone growth and turn-over in spontaneously diabetic BB rats. J Endocrinol 1992, 134:485-492.
4. Hui SL, Epstein S, Johnston CC: A prospective study of bone mass in patients with type I IDDM. J Clin Endocrinol Metab 1985, 60:74-80.
5. Mathiassen B, Nielsen S, Ditzel J, Rodboro P: Long-term bone loss in IDDM. J Intern Med 1990, 227:325-327.
6. Heath H: Bone mineral density in non-insulin-dependent diabetes. Ann Intern Med 1996, 125:253-255.
7. Conover CA, Lee PDK, Riggs BL, Powell DR: IGFBP-1 expression in cultured human bone cells: regulation by insulin and glucocorticoid. Endocrinology 1996, 137:3295-3301.
8. Tolk RP, Vandael PLA, Pols HAP, Burger H, Hofman A, Birkenhager JC, Lamberts SWJ, Grobbee DE: Hyperinsulinemia and BMD in an elderly population: the Rotterdam study. Bone 1996, 18:546-549.
9. Langdahl BI, Mortensen L, Vestervy A, Eriksen EF, Charles P: Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone 1996, 18:103-108.
10. Raisz LG: Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 1988, 318:818-828.
11. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, McMahon DJ, Bilezikian J: Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab 1995, 80:729-734. This is one of the classic studies examining the role of excess parathyroid hormone in BMD and the skeletal response to parathyroidectomy.
12. McDermott MT, Perloff JJ, Kidd GS: Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. J Bone Miner Res 1994, 9:509-514.
13. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM: An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical PTH and calcitonin therapy for osteoporosis. J Clin Invest 1993, 91:1138-1148.
14. Rosen CJ, Donahue LR: Parathyroid hormone and osteoporosis. Curr Opin Endocrinol Diabetes 1996, 3:532-539.
15. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR: Effect of HRT on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized controlled trial. Ann Intern Med 1996, 125:360-368. There are very few randomized trials in patients with primary hyperparathyroidism with respect to treatment options. Although this study involved only 42 women, it is an important trial that should set the stage for a multicenter study.
16. Britto JM, Fenton AJ, Holloway WR, Nicholson GC: Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994, 134:169-176.
17. Krohlner B, Vesterdal J, Jorgensen J, Pors Nielsen S: Spinal bone mineral content in myxedema and thyrotoxicosis: effects of thyroid hormone and anti-thyroid treatment Clin Endocrinol 1983, 18:439-446.
18. Rosen CJ, Adler RA: Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 1992, 75:1531-1534.
19. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrad E, Cauley J, Black D, Vogt TM, for the Study of Osteoporotic Fractures Research Group: Risk factors of hip fracture in white women. N Engl J Med 1995, 332:767-773. One of the risk factors for future hip fracture in the Study of Osteoporotic Fractures (a cohort study of > 9000 women) was a history of hyperthyroidism. This would suggest that even though bone mass is somewhat reversible with treatment, either the reversal is not complete or there are microarchitectural changes that revert after attainment of euthyroidism.
20. Solomon BL, Wartofsky L, Burman KD: Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 1993, 3:17-23.
21. Bauer DC: Thyroid hormone use and fractures. Arch Intern Med 1996, 156:341-342.
22. Duncan WE, Chang A, Solomon B, Wartofsky L: Influence of clinical characteristics and parameters associated with thyroid hormone therapy on the bone mineral density of women treated with thyroid hormone. Thyroid 1994, 4:183-189.
23. Faber J, Galloe AM: Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta analysis. Eur J Endocrinol 1994, 130:350-356.
24. Schneider DL, Barrett-Connor E, Morton DJ: Thyroid hormone use and bone mineral density in elderly women: effects of estrogen. JAMA 1994, 271:1245-1249.
25. Cushing H: Basophile adenomas. J Nerv Ment Dis 1932, 76:50-55.
26. Adler RA, Rosen CJ: Glucocorticoids and osteoporosis. Clin Endocrinol Metab 1994, 23:641-670.
27. Lems WF, Gerrits MI, Jacobs JWG, Vanvugt RM, Vanrijn HJM, Bijlsma JWJ: Changes in markers of bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996, 55:288-293.
28. Manning PJ, Evans MC, Reid IR: Normal bone density following cure of Cushing's syndrome. Clin Endocrinol 1992, 36:229-234.
29. Dobnig H, Stepan V, Leb G, Wolf G, Buchfelder M, Krejs GJ: Recovery from severe osteoporosis following cure from ectopic ACTH syndrome caused by an appendix carcinoid. J Intern Med 1996, 239:365-369.
30. Leong GM, Mercadoasis LB, Reynold JC, Hill SC, Oldfield EH, Chrousos GP: The effect of Cushing's disease on bone mineral density, body composition, growth and puberty: a report of an identical adolescent twin pair. J Clin Endocrinol Metab 1996, 81:1905-1911. This is a fascinating case report of Cushing's disease in a 15-year-old whose twin was normal. Bone density was low at the time of diagnosis and improved with cure of the disease, but after 2 years, bone mass still did not normalize. This finding suggests that treatment can reverse some bone loss but may permanently impair acquisition of peak bone mass.
31. Reid IR, Wattie DJ, Evans MC, Stapleton JP: Testosterone therapy in glucocorticoid treated men. Arch Intern Med 1996, 156:11:1173-1177. This trial (without placebo controls) is one of the first to suggest that androgens may protect against bone loss in men with steroid-treated asthma.
32. Struys A, Snelder AA, Mulder H: Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid induced osteoporosis. Am J Med 1995, 99:333-337.
33. Diamond T, McGuigan L, Barbagallo S, Bryant C: Cyclical etidronate plus ergocalciferol prevents glucocorticoid induced bone loss in postmenopausal women. Am J Med 1995, 98:459-463.
34. Healey JH, Paget SA, Williamsrusso P, Szatrowski TP, Schneider R, Spier H, Mitnich H, Ales K, Schwartzberg P: A randomized placebo controlled trial of salmon calcitonin to prevent bone loss in glucocorticoid treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996, 58:73-80. An interesting paper suggesting that parenteral calcitonin (100 U three times weekly) does not prevent steroid-induced bone loss.
35. Prior JC, Vigna Y, Schechter MT, Burgess AE: Spinal bone loss and ovulatory disturbances. N Engl J Med 1990, 323:1221-1227.
36. Slemenenda C, Longcope C, Peacock M, Hui S, Johnston CC: Sex steroids, bone mass and bone loss: a prospective study of pre-, peri-and postmenopausal women. J Clin Invest 1996, 97:14-21. A comprehensive longitudinal study of women ages 30 to 70 over 3 years examining determinants of bone mass and bone loss.
37. Rencken ML, Chestnut CH, Drinkwater BL: Bone density at multiple skeletal sites in amenorrheic athletes. JAMA 1996, 276:238-240. This is another cross-sectional study demonstrating the extent of osteopenia in amenorrheic athletes.
38. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WFJ: Osteoporosis in men with idiopathic hypogonadotrophic hypogonadism. Ann Intern Med 1987, 106:354-361.
39. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med 1994, 331:1056-1061.
40. Bing-you RG, Denis MC, Rosen CJ: Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum GH responses to GHRH, IGF-I and IGFBP-3. Calcit Tissue Int 1993, 52:183-187.
41. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson BA: Reduced bone mineral content in adults with GH deficiency. Acta Endocrinol 1993, 129:201-206.
42. Johannsson G, Rosen T, Bosaeus I, Sjostrom I, Bengstsson BA: Two years of growth hormone treatment increases bone mineral content and density in hypopituitary patients with adult onset GH deficiency. J Clin Endocrinol Metab 1996, 81:8:2865-2873. One of the most comprehensive studies to date on growth hormone replacement for growth hormone-deficient adults.
43. Halet SM: Growth hormone deficiency and replacement in adults: useful in those with reduced quality of life or bone mineral density. BMJ 1996, 313:314-318.
44. Whitehead HM, Boreham C, McIlrath EM, Sheridan L, Kennedy A, Atkinson B, Hadden DR: GH treatment of adults with GH deficiency: results of a 13 month placebo controlled cross-over study. Clin Endocrinol 1992, 36:45-52.
45. Rosen CJ, Kessenich CR: The role of IGF-I in senescence: clues for interventional strategies in the elderly. The Endocrinologist 1996, 6:102-108.